Despite being a curable disease, tuberculosis has remained a major global health threat for centuries [1] . According to the World Health Organization, an estimated 10.4 million new tuberculosis cases and 1.8 million deaths, including 0.4 million human immunodeficiency virus (HIV)-coinfected people, occurred in 2015 [2] . In addition, 25% of the worldwide population is latently infected with Mycobacterium tuberculosis, an intracellular pathogen capable of infecting and surviving within the host's mononuclear cells, particularly macrophages. Most immunocompetent individuals maintain latent M. tuberculosis infection (LTBI), with only 5%-10% lifelong risk of developing clinical disease [3] : the risk rises to 10% per year in HIV-coinfected individuals, owing to a lack of effective immunity, and extrapulmonary disease is more likely [4] .
The incidence of multidrug-resistant tuberculosis is increasing, in part because of nonadherence to lengthy treatment regimens. HIV coinfection has been associated with and may contribute to the increase in multidrug-resistant tuberculosis [5, 6] . Monitoring of the early treatment response is essential for effective administration of antituberculosis treatment to prevent drug resistance. Currently used diagnostic methods to confirm active tuberculosis and monitor antituberculosis treatment responses, such as sputum smear microscopy and mycobacterial culture, have low sensitivity for predicting treatment failure and relapse during antituberculosis treatment [7] , especially in HIV-coinfected individuals [8] because of the lower frequency of cavitary tuberculosis in this group. Another disadvantage of mycobacterial culture is the delay of several weeks before results become available and subsequent therapy adjustment. Existing immunological methods to diagnose M. tuberculosis infection, such as the tuberculin skin test (TST) and interferon-γ-release assays, cannot distinguish between LTBI and active tuberculosis and have poor sensitivity in children and immunocompromised
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individuals, including HIV-coinfected patients with tuberculosis [9] . Therefore, identification of biomarkers that classify clinical stages of tuberculosis and monitor antituberculosis treatment responses in HIV-coinfected individuals is essential for improving clinical practice.
The interaction between the host immune response and M. tuberculosis has major roles in determining the clinical outcome following infection with M. tuberculosis and whether tuberculosis drug treatment will result in cure. Changes in gene expression patterns in blood resulting from the elicited immune responses could potentially be used as biomarkers to classify the different clinical outcomes of exposure to M. tuberculosis [10] , including active disease or LTBI, and for monitoring antituberculosis treatment responses [11] [12] [13] . However, most studies have been conducted in HIV-uninfected subjects, with only very few studies showing that blood gene expression profiles can distinguish active tuberculosis from LTBI in HIV-coinfected individuals [14, 15] . Importantly, the combined effect of antituberculosis treatment and highly active anti-retroviral therapy (HAART) on host gene expression in HIV-infected individuals with tuberculosis has never been studied. Therefore, in this study we aimed to identify candidate host gene biomarkers that classify active tuberculosis in HIVcoinfected individuals and that can be used to monitor antituberculosis treatment responses in coinfected patients, including those taking HAART, using focused gene expression profiling by dual-color reverse-transcription multiplex ligation-dependent probe amplification (dcRT-MLPA).
MATERIALS AND METHODS

Ethics Statement
All study participants provided written, informed consent at enrollment. Ethical clearance was obtained from the Scientific and Ethics Research Office (reference EHNRI 6.13/01), the Ethiopian Public Health Research Institute, and the London School of Hygiene and Tropical Medicine Ethics Review Committee (reference 7174).
Study Design and Population
A longitudinal cohort study was conducted at the Akaki and Kality health centers of St. Peter's TB Specialized Hospital (Addis Ababa, Ethiopia) between April 2007 and January 2011. A total of 131 adults of both sexes aged 15-65 years old were enrolled. Participants were subdivided into the following 3 clinical study groups at enrollment and followed up at 6 (M6) and 18 (M18) months: (1) 48 HIV-infected patients with active tuberculosis (the active tuberculosis group), of whom 18 were receiving antituberculosis treatment and 13 were receiving antituberculosis treatment plus HAART at M6; (2) 37 HIV-infected TST-positive subjects (the LTBI group), of whom 20 were receiving HAART and 14 were naive to HAART at M6; and (3) 46 HIV-infected TST-negative subjects (the control group), of whom 26 were receiving HAART and 16 were naive to HAART at M6 (Supplementary Figure 1) . Patients who had received HAART for <3 months or who were lost during follow-up at M6 were excluded from the analysis.
At recruitment, study participants were interviewed by use of a standard questionnaire, and demographic data were collected. Exclusion criteria for enrollment were refusal of HIV testing, pregnancy, comorbidity with diabetes mellitus or chronic bronchitis, receiving steroid therapy, receiving tuberculosis and/or HAART treatment (at recruitment or previously), and alcohol or drug abuse that could compromise reliability. The initiation of HAART treatment at baseline or during follow-up visits was determined by the physician at the health center, using the national guidelines for ART [16] , including immunological criteria (ie, a CD4 + T-cell count of <200 cells/µL). HAART was provided free of charge to eligible patients. All active tuberculosis cases confirmed at enrollment were treated according to the national guideline [17] .
Diagnostic Assessment
HIV status was determined using the Determine HIV-1/2 screening test (Abbott laboratories, Tokyo, Japan), the Capilus HIV-1/2 confirmatory test (TrinityBiotec, Wicklow, Ireland), and the Unigold HIV-1/2 recombinant test (TrinityBiotec, Ireland) as a tiebreaker [17] . The CD4 + T-cell count was determined by flow cytometry, using the FACSCalibur platform (Becton Dickinson, USA), while the plasma HIV RNA load was determined using the NucliSensEasyQ NASBA diagnostic kit (OrganonTeknica, the Netherlands; detection range, 50-3 000 000 copies/mL).
A diagnosis of active tuberculosis was based on both clinical and bacteriological parameters. At least 2 sputum smears (a spot sample and an early morning sample) were required to be positive by microscopy for acid-fast bacilli, using the ZiehlNeelsen staining method (independent of the presence/absence of clinical parameters). There were no patients with dry cough in this study [17] . LTBI was determined by TST at baseline and follow-up visits for all participants except patients with active tuberculosis according to the national guidelines [17] . A total of 0.1 mL of tuberculin solution (RT23, State Serum Institute, Copenhagen) was injected intradermally into the dorsal surface of the forearm; TST positivity was classified as skin induration diameter of ≥5 mm in HIV-infected individuals [17] .
RNA Extraction
A total of 2.5 mL of venous blood was collected into PAXgene Blood RNA tubes (PreAnalytiX, Qiagen, Germany). RNA was extracted using the PAXgene Blood RNA extraction kit (PreAnalytiX, Qiagen) according to the manufacturer's instructions. Briefly, PAXgene tubes were centrifuged at 1800 × g for 10 minutes, and pellets were lysed, resuspended, and treated with proteinase K to remove contaminating proteins. Ethanol-precipitated nucleic acids were loaded onto spin columns, and DNA was digested using on-column RNase-free DNase (Qiagen). Purified RNA was eluted with RNase-free buffer (BR5 buffer) and quantified using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). RNA samples with a ratio of the absorbance at 260 nm to that at 280 nm of <1.70 or >2.3 were excluded from further analyses.
dcRT-MLPA
dcRT-MLPA was performed as previously described [12] . Briefly, for each target-specific sequence, we designed a specific RT primer, located immediately downstream of the left-and right-hand half-probe target sequence. RNA was reverse transcribed using an RT-primer mix and Moloney murine leukemia virus reverse transcriptase (Promega, USA). Transcriptase activity was inactivated by heating at 98°C for 2 minutes. Following reverse transcription, left-and right-hand half-probes were hybridized to the complementary DNA at 60°C overnight. Annealed half probes were ligated using ligase 65 and subsequently amplified by polymerase chain reaction (PCR) analysis (33 cycles of 30 seconds at 95°C, 30 seconds at 58°C, and 60 seconds at 72°C, followed by 1 cycle of 20 minutes at 72°C). Primers and probes were from Sigma-Aldrich Chemie (Zwijndrecht, the Netherlands), and MLPA reagents were from MRC-Holland (Amsterdam, the Netherlands). PCR amplification products were diluted 1:10 in HiDi-formamide containing 400HD ROX size standard, denatured at 95°C for 5 minutes, ice cooled, and analyzed on an Applied Biosystems 3730 capillary sequencer in GeneScan mode (BaseClear, Leiden, the Netherlands).
Trace data were analyzed using GeneMapper software 5 (Applied Biosystems). The areas of each assigned peak (calculated in arbitrary units) were exported for analysis in Microsoft Excel. Data were normalized to GAPDH, and signals below the threshold value for noise cutoff in GeneMapper (log 2 -transformed peak area, 7.64) were assigned the threshold value for noise cutoff. Finally, the normalized data were log 2 transformed for statistical analysis.
RT primers and half probes were designed at the Leiden University Medical Center [12, 18] and comprised sequences for 4 housekeeping genes and 105 selected genes to profile the innate and adaptive immune responses (Supplementary Table 1 ).
Statistical Analysis
A non-parametric Kruskal-Wallis test was performed to compare data between >2 clinical groups, while a 2-tailed Wilcoxon rank sum (Mann-Whitney) test for unpaired data or a Wilcoxon signed rank test for paired data was performed to compare data between 2 clinical groups. A χ 2 test was used to compare the different proportions of dichotomous variables among the groups. All data analysis was done using Intercooled Stata, version 11.0 (College Station, TX). The statistical significance cutoff was a P value of < .05.
RESULTS
Characteristics of the Study Population at Baseline
Of 131 HIV-infected study participants, 48 with active tuberculosis, 37 with LTBI, and 46 controls were included. Baseline demographic, clinical, and laboratory data for each study group are shown in Supplementary Tables 2A and 2B. The mean age (±SD) of individuals with active tuberculosis, patients with LTBI, and controls was 32.6 ± 7.8, 34.2 ± 8.02, and 32.8 ± 6.8 years, respectively, while 50%, 61%, and 72%, respectively, were female. Statistically significant differences between groups were observed in the proportion of patients with malnutrition (defined as a body mass index [calculated as the weight in kilograms divided by the height in meters squared] of <18.50) [19] and HIV-1 RNA load (Supplementary Table 2A ). Compared with individuals with LTBI and controls, patients with active tuberculosis presented with a lower body mass index (P = .0001 and .0013, respectively), a lower CD4 + T-cell count (P = .0335 and .0185, respectively), and a higher HIV RNA level (P = .028 and .046, respectively), whereas no significant differences in these parameters were observed between individuals with LTBI and controls.
Gene Expression Profiles of Clinical Stages of Tuberculosis in HIV-
Infected Individuals
Whole-blood gene expression profiles of 48 patients with active tuberculosis, 37 patients with LTBI, and 46 controls were analyzed by dcRT-MLPA, using probe sets for 105 selected genes, to profile innate and adaptive immune responses (Supplementary Table 1 ). Thirty-six of 105 genes examined were differentially expressed between the 3 clinical groups, and 26 of these genes discriminated between active tuberculosis and LTBI among HIV-coinfected individuals ( Data are median levels (interquartile ranges) of gene expression; areas were normalized to GAPDH and log 2 transformed. Only genes whose expression level significantly differed between any of the study groups are listed. P-values ≤ 0.05 are indicated in bold.
Abbreviations: Th, helper T cell; Treg, regulatory T cell.
a By the Wilcoxon Mann-Whitney test.
genes (PTPRCv2, IL1B, IL15, IL4δ2, IL9, IL22RA1, FLCN1,  TNFRSF1A, FPR1, CLEC7A, NLRC4, NLRP12, MMP9, LTF,  TLR1, TLR2, TLR4, TLR8, FCGR1A, RAB24, CD4, PTPRCv1,  TLR3 , BLR1, and ZNF331) that were differentially expressed between individuals with active tuberculosis and controls also discriminated between the active tuberculosis and LTBI groups ( Table 1 ), suggesting that these biomarkers are strongly associated with tuberculosis in HIV-coinfected individuals.
As expected, only a limited number of genes distinguished between the LTBI and control groups (Table 1) , in line with our previous studies in HIV-uninfected individuals [12] . Of the 10 genes that were differentially expressed, 4 (IL15, FPR1, TLR6, and SPP1) had significantly higher expression in individuals with LTBI as compared to controls, whereas 6 (CD3E, IL7R, TGFB1, GNLY, GZMB, and CCL5) had significantly lower expression.
Nonparametric receiver operator characteristic curves to determine the discriminatory potential of single genes identi- Figure 2 . Seven of 9 single genes that could discriminate between the active tuberculosis and control groups also discriminated between patients with active tuberculosis and those with LTBI, again suggesting that these coinciding biomarkers are strongly associated with tuberculosis in HIV-coinfected individuals. Genes that were differentially expressed between the LTBI and control groups had limited classifying value (AUCs of <0.70), as expected.
Transcriptomic Profiles of Antituberculosis Treatment Responses in HIV-
Coinfected Patients With Tuberculosis Are Independent of HAART
To determine whether (in)eligibility for HAART might be a confounding parameter in the analysis of antituberculosis treatment responses, individuals in each study group were stratified at baseline as either eligible or ineligible for HAART, and gene expression profiles were compared (Table 2 ). Clearly, very few genes were found to be differentially expressed within each study group when individuals were stratified on the basis of HAART in(eligibility). Of the 36 genes that were differentially expressed among the study groups before stratification, after stratification only 1 gene (IL4δ2) was differentially expressed among subjects with active tuberculosis, 5 (TNFRSF1A, TLR4, NLRC4, LTF, and BLR1) were differentially expressed among subjects with LTBI, and 3 (IL7R, GZMB, and TLR6) were differentially expressed among controls. Together, these data indicate that stratification on the basis of (in)eligibility for HAART is not a dominant confounding factor in the analysis of antituberculosis treatment responses.
Similarly, following 6 months of antituberculosis treatment and/or HAART therapy, only a limited number of genes was found to be differentially expressed within each study group on the basis of HAART (in)eligibility (Table 3) . Of the 36 genes that were found to be differentially expressed among the study groups before stratification on the basis of HAART in(eligibility), after stratification only 2 genes (TGFB1 and BLR1) were differentially expressed among subjects with active tuberculosis, 2 (GNLY and MMP9) were differentially expressed among subjects with LTBI, and 4 (IL7R, CCL19, TLR6, and MMP9) were differentially expressed among controls, suggesting that HAART merely affects the direct ex vivo RNA expression profile in the peripheral blood of HIV-infected individuals.
Importantly, while baseline biomarker profiles were identified in HIV-infected individuals that markedly discriminated patients with active tuberculosis from those with LTBI and uninfected controls (Table 1) , longitudinal follow-up analysis showed that biomarker profiles of treated patients with active tuberculosis became indistinguishable from those with LTBI and controls at the end of 6 months of tuberculosis therapy. This outcome was independent of HAART (in)eligibility and HAART receipt (Tables 4 and 5 and Supplementary Figure 2) . In summary, these data show that transcriptomic profiles of antituberculosis treatment responses in HIV-coinfected patients with tuberculosis are independent of HAART receipt and normalize to levels observed in subjects with LTBI and controls after completion of antituberculosis treatment.
DISCUSSION
Identification of biomarkers that can discriminate between active tuberculosis and LTBI is essential for controlling the spread of tuberculosis worldwide, especially in HIV-infected subjects. Furthermore, biomarkers that can monitor antituberculosis treatment responses and evaluate antituberculosis treatment efficacy could potentially reduce de novo drug resistance development [20] . Here, we used a focused gene expression profiling platform, dcRT-MLPA [12] , targeting innate and adaptive immune response genes, to analyze RNA expression levels of 105 preselected genes in peripheral blood specimens from HIV-infected individuals and identified biomarkers with excellent discriminatory capacity. At baseline, expression levels of 7 single genes (FCGR1A, RAB24, TLR1, TLR4, MMP9, NLRC4, and IL1B) could accurately discriminate between patients with active tuberculosis and both patients with LTBI and controls, with AUCs of ≥75, indicating these interrelating biomarkers are strongly associated with tuberculosis in HIV-coinfected individuals. In contrast, all genes that were differentially expressed between the LTBI group and the control group had limited classifying value (AUC <70), in accordance with previous studies in HIV-uninfected populations [12] . The observed higher expression of immune-related genes in HIV-infected individuals with active tuberculosis may be due to an increased load of bacterial antigens from actively replicating bacilli, triggering a vigorous host immune response. In contrast, lower expression of T-cell-associated genes (eg, CD4 and PTPRCv1) in these patients with tuberculosis may reflect HIV-related cell depletion and/or cell migration to the lungs as the primary infection site. This peripheral T-cell depletion may be one underlying mechanism by which tuberculosis aggravates HIV infection progression [21] .
TGFB1 expression was significantly higher in HIV-infected participants with active tuberculosis as compared to those with LTBI, in contrast to previous reports involving HIV-uninfected participants in South Africa and Malawi [15] . TGFB1 is involved in the induction of fibrosis, a hallmark presentation of tuberculosis, and excessive TGFB1 during tuberculosis may enhance viral activity, thereby accelerating HIV disease [22] . . Gene expression profiles of signature genes. Box and whisker plots of median levels (95% confidence intervals) of gene expression (areas were normalized to GAPDH and log 2 transformed). Shown are individual genes that were found to have the best discriminatory power to distinguish between individuals with active tuberculosis (active group) versus those with latent Mycobacterium tuberculosis infection (LTBI group) and those with negative results of tuberculin skin tests (control group). *P ≤ 0.05, **P ≤ 0.01, ***P≤ 0.001, and ****P ≤ 0.0001, by the Kruskal-Wallis H test (for differences among groups) and the Wilcoxon Mann-Whitney test (for differences between groups).
Concentrations of TGFB1 cytokine were about 2-fold higher in PPD-induced culture supernatants for HIV-infected patients with tuberculosis [23] . Therefore, elevated levels of TGFB1 expression in patients coinfected with M. tuberculosis and HIV may result in enhanced T-cell suppression and propagation of HIV and M. tuberculosis. Data are median levels (interquartile ranges) of gene expression; areas were normalized to GAPDH and log 2 transformed. Study groups comprised human immunodeficiency virus-infected individuals with active tuberculosis (active group), those with latent Mycobacterium tuberculosis infection (LTBI group), and those with negative results of tuberculin skin tests (control group). Genes listed in this table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1) . P-values ≤ 0.05 are indicated in bold.
Within our HIV-infected cohort, FCGR1A was among the strongest differentially expressed genes, with marked discriminatory power between the active tuberculosis group and both the LTBI group and control group. This is consistent with gene expression profiles of peripheral blood mononuclear cells and whole-blood specimens from patients with tuberculosis and Chemokine CCL19 9.5 (9.3-9.8) 9.6 (9.4-10.0) .2185 9.5 (9.3-9.9) 9.5 (9.3-9.7) .5534 9.7 (9.5-9.9) 9.5 (9.3-9.7) .0325
Pattern-recognition receptors .5303 9.4 (9.1-10.0) 9.7 (9.4-10.0) .3096 9.1 (8.7-9.5) 9.6 (9.2-9.9) .0480 TLR8 10.7 (7.6-11.5) 10.1 (7.6-11.2) .5711 9.9 (8.5-11.0) 10.5 (9.4-11.1) .3738 10.5 (9.0-11.3) 9.9 (8.8-10.9) .3425
Inflammasome components NLRC4 9.1 (8.9-9.3) 9.0 (8.9-9.2) .4297 9.3 (9.2-9.6) 9.4 (9.1-9.6) .8989 9.3 (9.2-9.4) 9.3 (9.1-9.5) .9361 NLRP12 8.0 (7.6-8.7) 8.0 (7.7-8.7) .5125 7.9 (7.6-8.3) 8.4 (7.7-8.6) .2152 7.8 (7.6-8.1) 7.8 (7.6-8.4) .4592 .0215 SPP1 7.7 (7.6-8.2) 7.7 (7.6-9.1) .5516 7.8 (7.6-7.9) 8.3 (7.6-8.5) .0606 8.0 (7.6-8.6) 7.6 (7. Data are median levels (interquartile ranges) of gene expression; areas were normalized to GAPDH and log 2 transformed. Study groups comprised human immunodeficiency virus-infected individuals with active tuberculosis (active group), those with latent Mycobacterium tuberculosis infection (LTBI group), and those with negative results of tuberculin skin tests (control group). Genes listed in this table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1) . P-values ≤ 0.05 are indicated in bold.
IFN signaling gene
Abbreviations: Th, helper T cell; Treg, regulatory T cell. Data are median levels (interquartile ranges) of gene expression; areas were normalized to GAPDH and log 2 transformed. Study groups comprised human immunodeficiency virus-infected individuals with active tuberculosis (active group), those with latent Mycobacterium tuberculosis infection (LTBI group), and those with negative results of tuberculin skin tests (control group). Genes listed in this table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility (Table 1) . P-values ≤ 0.05 are indicated in bold.
a By the Wilcoxon signed rank test.
b By the Wilcoxon Mann-Whitney test.
healthy donors in HIV-uninfected populations of different ethnic backgrounds [24] [25] [26] . Moreover, Sutherland et al recently reported transcript levels of FCGR1A as the most reliable classifier of active tuberculosis compared to LTBI and M. tuberculosis-uninfected controls regardless of HIV status and genetic background [15] . FCGR1A is an essential component Data are median levels (interquartile ranges) of gene expression; areas were normalized to GAPDH and log 2 transformed. Study groups comprised human immunodeficiency virus-infected individuals with active tuberculosis (active group), those with latent Mycobacterium tuberculosis infection (LTBI group), and those with negative results of tuberculin skin tests (control group). Genes listed in this table were differentially expressed between any of the study groups before stratification by HAART (in)eligibility ( of interferon signaling and plays a central role in endocytosis, phagocytosis, antibody-dependent cellular toxicity, cytokine release, and superoxide generation [27] but may participate in tuberculosis pathogenesis. Transcript levels of TLR1, TLR2, TLR4, RAB24 and MMP9 were also higher in patients with active tuberculosis as compared to patients with LTBI and controls, in agreement with published data in HIV-uninfected subjects [28, 29] , suggesting that a biomarker signature encompassing these genes and also including FCGR1A may be useful in classifying different clinical stages of tuberculosis in both HIV-uninfected and HIV-infected individuals. Although these genes display comparable expression patterns between study groups and similar expression kinetics during tuberculosis treatment, their functional roles during M. tuberculosis infection is diverse. RAB24 is involved in intracellular trafficking [30] , and the increase in RAB24 expression in M. tuberculosis-infected monocytes has been correlated to increased autophagic activity [29] . Pattern-recognition receptors are the first line of recognition of M. tuberculosis bacilli and have a critical role in initiating innate and subsequent adaptive immune responses. TLR1 and TLR2 play an important role in host defense against mycobacteria, especially by mediating responses to mycobacterial triacylated lipopeptides [31] . In addition, the ability of M. tuberculosis to inhibit major histocompatibility complex class II expression and antigen presentation through stimulation of TLR2 and TLR1 creates a niche for survival of M. tuberculosis in macrophages and promotes its evasion of recognition by CD4 + T cells [28] . Finally, higher expression levels of MMP9 have been shown to correlate with dysregulation of cellular apoptosis in patients with HIV and M. tuberculosis coinfection [32] and with early dissemination of M. tuberculosis followed by recruitment of macrophages, induction of helper T-cell type 1 immunity, and formation of granulomas [33] .
The patients with LTBI recruited into this study likely reflect a heterogeneous group of individuals, including some with quiescent M. tuberculosis infection and others with asymptomatic subclinical disease [34] ; future work could test whether the gene expression signatures are able to discriminate these subgroups. Additionally, the active tuberculosis group only included individuals with a microbiologically case; future work could determine the usefulness of gene expression in a wider range of clinically suspected tuberculosis cases.
Most genes that were differentially expressed at baseline between subjects with active tuberculosis and those with LTBI or uninfected controls underwent normalization in HAART recipients during antituberculosis treatment to levels observed in (HAART-recipient) patients with LTBI and uninfected controls. Normalization of gene expression profiles in patients with tuberculosis during 6 months antituberculosis chemotherapy has previously been reported in HIV-uninfected patients with tuberculosis [10, 35, 36] and correlates with clinical cure [11] . Interestingly, only a few genes were differentially expressed at baseline between study groups eligible and ineligible for HAART, excluding (in)eligibility for HAART as a confounding factor when analyzing the kinetic response of antituberculosis treatment at the transcriptomic level. Moreover, HAART use by eligible patients with active disease, patients with LTBI, and controls only marginally affected transcriptomic profiles. This suggests that a similar biomarker signature can be used to monitor antituberculosis treatment efficacy in patients coinfected with M. tuberculosis and HIV both eligible and ineligible for HAART.
In conclusion, the expression of several single genes (FCGR1A, RAB24, TLR1, TLR4, MMP9, NLRC4, and IL1B) in peripheral blood can discriminate HIV-infected individuals with active tuberculosis from those with LTBI and those without M. tuberculosis infection. These biomarkers can also be used to monitor antituberculosis treatment responses in HIV-infected individuals independent of HAART (in)eligibility and receipt. Potentially, in the future, the identified biomarkers could be used to facilitate evaluation of new tuberculosis chemotherapeutic regimens and for vaccines trials, regardless of HAART.
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